Inovio Pharmaceuticals Newsroom

Inovio Pharmaceuticals' INO-3107 Shows Promising Clinical Trial Results, Earns 'Buy' Rating From Analyst

TipRanksDec 5 23:29

Analysts Are Bullish on These Healthcare Stocks: Inovio Pharmaceuticals (INO), Replimune Group (REPL)

TipRanksDec 5 23:23

Oppenheimer Maintains Inovio Pharmaceuticals(INO.US) With Buy Rating, Cuts Target Price to $15

Futu NewsNov 19 16:39

Inovio Pharma Price Target Cut to $5.00/Share From $12.00 by HC Wainwright & Co.

Dow JonesNov 19 00:47

Oppenheimer Maintains Outperform on Inovio Pharmaceuticals, Lowers Price Target to $15

BenzingaNov 18 21:56

Cautious Hold Recommendation on Inovio Pharmaceuticals Amid Financial Challenges and Competitive Pressures

TipRanksNov 18 19:32

JMP Securities Maintains Inovio Pharmaceuticals(INO.US) With Buy Rating, Maintains Target Price $18

Futu NewsNov 18 14:31

Inovio Pharmaceuticals: Strategic Progress and Promising Pipeline Justify Buy Rating

TipRanksNov 18 13:37

Inovio Pharma Is Maintained at Sector Perform by RBC Capital

Dow JonesNov 16 01:42

Inovio Pharmaceuticals Analyst Ratings

BenzingaNov 16 01:31

RBC Capital Maintains Inovio Pharmaceuticals(INO.US) With Hold Rating, Cuts Target Price to $6

Futu NewsNov 15 20:33

RBC Capital Sticks to Its Hold Rating for Inovio Pharmaceuticals (INO)

TipRanksNov 15 19:48

Inovio Pharma Is Maintained at Sector Perform by RBC Capital

Dow JonesOct 4 23:53

Inovio Pharmaceuticals Analyst Ratings

BenzingaOct 4 23:43

RBC Cuts Price Target on Inovio Pharmaceuticals to $7 From $8, Keeps Sector Perform, Speculative Risk

MT NewswiresOct 4 19:34

Inovio Pharma Price Target Cut to $33.00/Share From $40.00 by Oppenheimer

Dow JonesAug 12 21:51

Analysts Offer Insights on Healthcare Companies: Universal Health (UHS) and Inovio Pharmaceuticals (INO)

TipRanksAug 12 20:29

Inovio Pharmaceuticals (INO) Receives a Buy From Oppenheimer

TipRanksAug 12 20:08

Inovio Pharmaceuticals Analyst Ratings

BenzingaAug 10 03:24

RBC Capital Maintains Sector Perform on Inovio Pharmaceuticals, Lowers Price Target to $8

BenzingaAug 10 03:24